Business Context and Reporting Period
This Form 8-K Current Report was filed by Allogene Therapeutics, Inc. on January 23, 2025. The report discloses a material corporate event regarding the departure of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Executive Departure: Timothy Moore agreed to leave his employment with the Company effective February 28, 2025.
- Severance Terms: The departure is classified as a termination without cause. Mr. Moore is eligible for cash severance and COBRA reimbursement benefits under the Company's Change in Control and Severance Benefit Plan, contingent upon providing an effective release and waiver of claims.
- Future Engagement: The Company intends to enter into a consulting agreement with Mr. Moore, subject to mutual agreement on terms.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, or specific risk factors beyond the standard disclosure of the executive departure. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the specific terms of the consulting agreement to be negotiated with Timothy Moore.
- Review the Company's Change in Control and Severance Benefit Plan to understand the exact calculation of severance benefits.
- Monitor subsequent filings for the appointment of a replacement for Mr. Moore's role.